It is the basis for regulatory approval for JAKi, and it is a clear measure of efficacy as it is associated with better clinical outcomes and improved QoL. However, it is not the end-all, be-all for endpoints. As we design studies to test new therapies, we need to move beyond SVR and TSS50 to endpoi...